StreetInsider.com News Articles

Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral

Thu, 24 Sep 2026 05:32:32 -0400

(Updated - September 24, 2026 5:32 AM EDT)

Goldman Sachs analyst Andrea Newkirk resumes coverage on AbCellera Biologics (NASDAQ: ABCL) with a Neutral rating and a price target of $13.00.

The analyst comments "ABCL is a clinical-stage biotechnology company that leverages a proprietary, vertically integrated engine of high-throughput technologies, data science, and machine learning to discover and develop antibodies. While historically focused on partner-initiated programs to generate downstream economics per future milestone and royalty streams (thus mitigating binary risk associated with any one program), the company has more recently prioritized development of its internal pipeline, including clinical-stage candidates ABCL635 for menopausal vasomotor

Goldman Sachs Resumes AbCellera Biologics (ABCL) at Neutral

Thu, 24 Sep 2026 05:32:32 -0400

(Updated - September 24, 2026 5:32 AM EDT)

Goldman Sachs analyst Andrea Newkirk resumes coverage on AbCellera Biologics (NASDAQ: ABCL) with a Neutral rating and a price target of $13.00.

AbCellera to present Phase 2 data on menopause drug at IMS congress

Wed, 16 Sep 2026 16:05:12 -0400

AbCellera Biologics (Nasdaq: ABCL) announced it will present Phase 2 data on its investigational drug ABCL635 at the International Menopause Society 20th World Congress on Menopause, scheduled for September 30 to October 3, 2026, in Rio de Janeiro, Brazil.

The oral presentation, titled "Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms," is scheduled for October 1, 2026, from 8:30 a.m. to 9:30 a.m. GMT-3 at the Windsor Oceânico Hotel and Congress Center.

AbCellera will present efficacy and safety data from its Phase 2 trial in postmenopausal women with moderate-to-severe vasomotor

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Wed, 16 Sep 2026 16:05:00 -0400

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30 to October 3, 2026 at the Windsor Oceânico Hotel and Congress Center in Rio de Janeiro, Brazil.

Details on AbCellera’s oral presentation at IMS are as follows:

Title: Interim Results of a Phase 1/2 Study of ABCL635, a First-in-Class NK3R Monoclonal Antibody for the Treatment of Vasomotor Symptoms
Abstract ID: 16836
Session: Symptoms of Menopause 1
Date and Time: Thursday,

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

Wed, 16 Sep 2026 16:05:00 -0400

Details on AbCellera’s oral presentation at IMS are as follows:

Form 4 AbCellera Biologics Inc. For: Aug 24 Filed by: Hayden Michael R

Mon, 24 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26969183.html

Form 4 AbCellera Biologics Inc. For: Aug 24 Filed by: Hayden Michael R

Mon, 24 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26969183.html

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

Wed, 19 Aug 2026 08:56:00 -0400